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Available online 14 November 2015Reoccurrence of symptoms occurs in 30–50% of coronary artery disease patients receiving vein grafts or bare-
metal stents due to intimal thickening (restenosis). Restenosis is caused by vascular smooth muscle cell
(VSMC)migration and proliferation. New therapeutic approaches that reduce VSMCmigration and proliferation
while promoting endothelial cell (EC) coverage are required. We assessed the effect of a soluble form of N-
cadherin (SNC-Fc, a fusion of the extracellular portion of N-Cadherin to a mutated Fc fragment of IgG), a cell–
cell junction molecule, on human saphenous VSMC proliferation and migration in vitro. We also assessed its
effect on intimal thickening in a validated human ex vivo organ culture model. We observed that SNC-Fc signif-
icantly inhibited VSMC proliferation and to a lesser extent migration. The anti-proliferative effect of SNC-Fc was
mediated by the interaction of SNC-Fc with the FGFR, rather than through inhibition of β-catenin signalling. SNC-
Fc also signiﬁcantly reduced intimal thickening by ~85% in the ex vivo organ culture model. SNC-Fc treatment
inhibited proliferation of the intimal cells but did not affect migration. SNC-Fc reduced EC apoptosis, without
detrimental effects on EC proliferation and migration in vitro. Importantly SNC-Fc increased EC coverage in the
ex vivo model of intimal thickening. In conclusion, we suggest that SNC-Fc may have potential as an anti-
proliferative therapeutic agent for reducing restenosis which has no detrimental effects on endothelial cells.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Keywords:
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Cadherin1. Introduction
Atherosclerosis is the underlying pathology of many cardiovascular
diseases. Treatments for atherosclerosis such as vein grafting and stent
implantation have a high failure rate due to restenosis [1,2]. Restenosis
is caused by intimal thickening as a result of inappropriate vascular
smoothmuscle cell (VSMC) activation, and superimposed atherosclero-
sis [3]. Current drug-eluting stents are coated with anti-proliferative
treatments such as rapamycin,which dramatically reduce intimal thick-
ening but result in higher thrombosis rates due to endothelial damage
[2]. Furthermore, a clinically-proven pharmacological intervention for
reduction of vein graft restenosis is not currently available. There is,
therefore, still a need to identify novel treatments for intimal thickening
(and thereby restenosis), which reduce VSMC migration and prolifera-
tion, whilst escaping detrimental effects on endothelial cell (EC) surviv-
al, migration and proliferation, as recently reviewed [4].
Homophilic cell–cell adhesions aremediated in VSMCs by cadherins,
predominantly N-cadherin [5]. We have previously shown that
cadherin-mediated cell–cell adhesion acts as a negative regulator of
VSMC proliferation [5–8]. Cadherin:catenin complexes are dismantled
during proliferation in cultures of isolated human saphenous vein. This is an open access article underVSMCs [5] and after balloon injury of rat carotid arteries [8]. Dismantling
of N-cadherin is mediated by MMP-dependent shedding from the cell
surface, resulting in translocation of β-catenin to the nucleus [5] and
up-regulation of cyclin D1 expression [7]. The role of N-cadherin in
VSMC migration is less clear; one study showed that N-cadherin pro-
motesmigration [9], while another showed that N-cadherin inhibitsmi-
gration [10]. N-cadherin can also affect the behaviour of endothelial
cells [11,12].
N-cadherinmay also modulate VSMC proliferation andmigration by
interactingwith the FGFR via a common HAV bindingmotif [13,14]. We
have previously observed that this interaction promoted VSMC survival
[12]. Fibroblast growth factor (FGF) induces internalisation of FGF re-
ceptor (FGFR), followed by nuclear translocation, where FGFR acts as a
general transcription regulator, activating the transcription of genes,
such as FGF-2 and CREB, which are essential for proliferation [15]. E-
cadherin is co-internalised with FGFR1 in human breast adenocarcino-
ma cells (MCF-7). Furthermore, overexpression of E-cadherin prevents
the nuclear translocation of FGFR1 [16].
Soluble forms of cadherins, consisting only of the extracellular
domain, can mimic the full-length form, inhibiting cell–cell adhesion
but promoting responses that are normally stimulated by full length
cadherins [11,13]. Soluble N-cadherin also contains the HAV binding
domain, enabling FGF-R binding. Soluble N-cadherin (SNC-Fc) is more
suitable as a therapeutic than full length N-cadherin as it is smaller,the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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creased endothelial cell migration using thewounding assay and angio-
genesis in the cornea [11], and we have previously shown that soluble
N-cadherin signiﬁcantly increased endothelial cell survival as well as
VSMC survival [12].
In this study, we have investigated the effect of soluble N-cadherin
on VSMC and endothelial cell proliferation and migration, and exam-
ined the signalling pathways involved. Additionally we have utilised a
human ex-vivo organ culture model to investigate the effect of soluble
N-cadherin on intimal thickening.
2. Materials and methods
2.1. Cell culture (VSMCs and HUVECs)
Human saphenous vein VSMCs at passage 2–8were generated as de-
scribed previously [5] from consenting patients undergoing coronary
artery bypass surgery (Research Ethics Committee #04/Q2007/6, in ac-
cordance with the ethical standards laid down in the 1964 Declaration
of Helsinki and its later amendments). Each experiment was performed
with VSMCs from segments of vein from at least 3 different patients.
Three separate preparations of human umbilical vein endothelial cells
(HUVECs)were purchased fromPromoCell andwere cultured following
the supplier's instructions.
2.2. Adenovirus production
Recombinant adenoviruses termed RAd FLNC, RAd SNC-Fc and RAd
Fc (control) to over-express full lengthN-cadherin, the extracellular do-
main of N-cadherin conjugated to Fc or the Fc domain alone, respective-
ly, were produced, as described previously [12]. The chimeric molecule
comprised of SNC-Fc and mouse immunoglobulin G constant domain
(with mutated Fc receptor and complement binding domains), enables
protein A binding, aswell as extending plasma half-life, and possibly in-
creasing receptor–ligand interaction.
2.3. Mutation of SNC-Fc
Two fragments of SNC-Fc were cloned. The ﬁrst contained the HAV
and INPISGQ motifs, which are required for interaction with N-
cadherin [17]. The second contained the IDPVNGQ motif, which is re-
quired for interaction with FGFR1 [17]. PCR mutagenesis was used to
mutate the binding sites of SNC-Fc as previously described [18], and
the mutated fragments were returned to SNC-Fc. Two plasmids were
produced: “SNC-Fc N-Cadmut” and “SNC-Fc FGFRmut”.
2.4. Puriﬁcation of Fc, SNC-Fc, and the mutated forms of SNC-Fc
CHO cells were infected with 50 pfu/cell of RAd Fc or RAd SNC-Fc, or
alternatively transfected using Amaxa nucleofection with the mutated
SNC-Fc plasmids following the manufacturer's instructions. The condi-
tioned media was collected at 66 and 138 h after infection. Conditioned
media was pooled and puriﬁcation achieved with protein A columns
(Amersham Biosciences). Protein concentrations were determined
using the Bradford Protein assay (Sigma).
2.5. Assessment of proliferation
Proliferation in the presence of 20 ng/ml platelet-derived growth
factor-BB (PDGF-BB) and 20 ng/ml basic ﬁbroblast growth factor
(bFGF) for VSMCs, or complete endothelial cell media for HUVECs,
was assessed by bromodeoxyuridine (BrdU, Pubmed CID: 6035) in-
corporation by immunocytochemistry as previously [7,19], and by
immunocytochemistry for proliferating cell nuclear antigen (PCNA,
see below)., VSMCs were subconﬂuent at the time of treatment.
PDGF and bFGF were added at the same time as Fc or SNC-Fc to assessthe effect of SNC-Fc on proliferation. In some experiments VSMCs
were additionally treated with 30 μM SU5402 (Calbiochem) or
siRNA (see below), to inhibit FGFR signalling, or transfected with
FGFR1 (SP/NLS) to overexpress constitutively nuclear FGFR1. 150–
200 cells were counted per condition to assess the percentage of
proliferating cells.
2.6. Assessment of migration
The migration of VSMCs was determined by plating 4 × 104 cells in
24well plates with 10% (v/v) foetal calf serum and assessed by a scratch
wound assay, as described previously [19]. Brieﬂy, 4 h after plating, cells
were pre-treated with Fc or SNC-Fc for 24 h then themonolayer of cells
was scratched with a 1ml pipette tip and treated with Fc or SNC-Fc and
2 μM hydroxyurea (Pubmed CID: 3657) for a further 18 h. The wound
was photographed and themigrated distance calculating by subtracting
thewound size at 18 h from thewound size at 0 h. Chemotaxis of VSMCs
treated with Fc or SNC-Fc was determined using the Boyden chamber
method, as described previously [20].
2.7. Immunocytochemistry
Cells were ﬁxed with 3% paraformaldehyde (Pubmed CID: 712),
permeabilised with 1% Triton X-100 (Pubmed CID 5590), blocked in
20% goat serum, incubated with FGFR antibody (R&D systems) dilut-
ed1:100 (5 μg/ml) or PCNA antibody from Abcam (ab18197), diluted
1:700 (1 μg/ml), followed by anti-mouse biotinylated secondary anti-
body (DAKO) or anti-rabbit biotinylated secondary antibody (DAKO),
and Alexa ﬂuor 488 anti-streptavidin (Life Technologies), andmounted
in Prolong Gold with DAPI (Molecular Probes).
Dual immunocytochemistry for BrdU and β-galactosidase: brieﬂy,
cells were ﬁxed with 3% paraformaldehyde, permeabilised with 1%
Triton, treated with 2 N HCl, blocked in 20% goat serum, incubated
with the BrdU (Sigma, 1:500) and β-galactosidase (Abcam, ab9361,
1:1000) primary antibodies, followed by anti-chicken biotinylated
secondary antibody (DAKO), and Alexa ﬂuor 488 anti-streptavidin and
anti-mouse (Life Technologies), mounted without DAPI.
2.8. β-catenin signalling
TOPgal transgenic mouse VSMCs were grown from aortic explants,
as described previously [7]. These VSMCs contain the β-galactosidase
gene under the control of TCF responsive elements. TOPgal VSMCs
were treated with 0.01% (w/v) trypsin, 1 mM CaCl2 (Pubmed CID
5284359), in phosphate-buffered saline (PBS) and seeded into a 24
well plate in the presence of SNC-Fc or Fc and 20 ng/ml PDGF-BB and
20 ng/ml bFGF to induce proliferation. β-galactosidase activity was
quantiﬁed using the chemiluminescent Galactolight assay (Tropix) as
described by the manufacturer's instructions. Further quantiﬁcation
was achieved using dual immunocytochemistry for BrdU and β-
galactosidase (see above).
2.9. Western blot analysis and immunoprecipitation
SDS lysed cell extracts were subjected to Western blotting as de-
scribed previously [5]. Blots were incubated overnight at 4 °C with
primary antibodies diluted in 5% BSA/TBS. Antibodies were used at
the following concentrations: N-cadherin (BD Biosciences: 610920,
1:2500), GAPDH (Chemicon: MAB374, 1:5000), and FGFR1 (R&D
Systems: MAB658, 1:50). Bound antibodies were detected by rabbit
anti-mouse or swine anti-rabbit horseradish peroxidase conjugated
antibodies (Dako) and enhanced chemiluminescence (Amersham
International). Stain free gel (BioRad) loading controls were used
in some experiments. Fc tag was detected using the goat-anti-
mouse secondary antibody (diluted 1:1000 in 5% Marvel in TBS-T).
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GFP was overexpressed in full media using AMAXA (following the
manufacturer's instructions) in 4 T25 ﬂasks. After 24 h cells were treat-
ed with nothing (control), 200 pM Fc, SNC-Fc or SNC-Fc FGFR1mut in
serum free media for 1 h. Cells were lysed in 400 μl RIPA buffer with
complete protease inhibitor (Roche). Lysates were incubated on a rota-
tor at 4 °C with GFP-agarose beads (abcam: ab69314) overnight, centri-
fuged andwashed twice with RIPA buffer. The beads were resuspended
in 30 μl Laemmli buffer (BioRad), and boiled at 95 °C for 5 min before
loading onto a Western blot as described above. Fc tag detection was
used.
2.10. FGFR1 siRNA knockdown
Two HP validated silencing RNA oligonucleotides (siRNA) for FGFR1
or control (Allstars Negative control siRNA) were purchased from
Qiagen (catalogue numbers SI02224677, SI02224684 and 1027281).
To conﬁrm this, we additionally used siRNA oligonucleotides
(FGFR and control) purchased from Santa Cruz (sc29316 and
sc37007). VSMCs (8 × 105) were subjected to Amaxa nucleofection
with 250 pmol of FGFR1 or control siRNAs using the VSMC kit and
U-25 programme following the manufacturer's instructions (Amaxa).
VSMCs for proliferation analysis were seeded in serum free media and
were treated with 100 pM Fc/SNC-Fc and proliferation induced with
20 ng/ml PDGF 24 h after nucleofection. Silencing was validated by
quantitative PCR as described previously and below [6,21], primers
are shown in Table 1. Protein knockdown was assessed by Western
blotting (as described above) and by immunocytochemistry for FGFR1
(see above).
2.11. Plasmid overexpression
GFP-tagged ORF clone of Homo sapiens ﬁbroblast growth factor re-
ceptor 1 (FGFR1), transcript variant 3 as transfection-ready DNA was
purchased from Insight Biotechnologies. VSMCs (8 × 105) were subject-
ed to Amaxa nucleofection with 5 μg of FGFR1 plasmid as outlined
above. VSMCs were seeded in full media, then changed to serum free
media after 18 h. Following 4 h in serum free media, VSMCs were treat-
edwith 20, 100 and 200 pMFc/SNC-Fc in the presence of 20 ng/ml bFGF
and 20ng/ml PDGF. 4 h later, VSMCswereﬁxed andmounted in Prolong
Gold with DAPI (Molecular Probes) and the percentage of cells with nu-
clear FGFR1 was calculated.
Constitutively nuclear FGFR1 (FGFR1 (SP/NLS)) was a kind gift from
Professor Michal Stachowiak, University at Buffalo, New York City.
VSMCs (8 × 105) were subjected to Amaxa nucleofection with 5 μg of
FGFR1 (SP/NLS) plasmid as outlined above. VSMCs were seeded in full
media, then changed to serum free media after 18 h. Following 4 h in
serum free media, VSMCs were treated with 200 pM Fc or SNC-Fc in
the presence 20 ng/ml bFGF and 20 ng/ml PDGF. Proliferation was
assessed by BrdU analysis after 24 h.
2.12. qPCR
Quiesced VSMCs were incubated with 20 ng/ml bFGF and 20 ng/ml
PDGF in the presence of 200 pM Fc or SNC-Fc for 6 h and total RNATable 1
QPCR primers.
Primer name Sequence/catalogue number Company
p21 F: 5′-AGGATCCATGTCAGAACCGGCTGG-3′
R: 5′-CAGGATCCTGTGGGCGGATTAGGG-3′
Sigma
Cyclin D1 F: 5′-AGTAGCAGCGAGCAGCAGAGT-3′
R: 5′-TTCATCTTAGAGGCCACGAA-3′
Sigma
18S F:5′-CGCGGTTCTATTTTGTTGGT-3′
R: 5′-CTTCAAACCTCCGACTTTCG-3’
Sigma
FGFR1 QT00102837 Qiagenwas extracted usingmiRNeasy kit (Qiagen) according tomanufacturer's
instructions. cDNA was derived using Transcriptor ﬁrst strand cDNA
synthesis kit (Roche) and subjected to quantitative PCR as described
previously [6,21] for cyclin D1, p21 and 18 s ribosomal RNA using
primers (see Table 1) and Lightcycler 480 SYBR green I master
(Roche) in accordance with manufacturer's instructions. Quantiﬁcation
of cyclin D1 and p21 messenger RNA (mRNA) was achieved after nor-
malisation to 18 s ribosomal mRNA copies.
2.13. Human saphenous vein organ culture
Surplus segments of human saphenous vein (n = 5 different pa-
tients) were obtained from patients undergoing coronary artery bypass
surgery and placed in organ culture as described previously [22]. This
study was reviewed by the relevant ethics committee (REC number
04/Q2007/6), and therefore was performed in accordance with the eth-
ical standards laid down in the 1964Declaration of Helsinki. Endothelial
denudation occurs during surgical preparation of vein [23,24] conse-
quently, we did not induce further endothelial denudation. The average
endothelial coverage via QBend10 at time zero was 56.2 ± 8.7%. Seg-
ments of vein were cut open longitudinally then divided into 2 pieces
crosswise, one was treated with 20 pM Fc and the other with 20 pM
SNC-Fc and 10 μM BrdU and organ culture was performed as described
previously [20]. Three micrometre parafﬁn-wax sections were stained
with haematoxylin and eosin, and Miller's elastic van Gieson stain. Inti-
mal thickness was quantiﬁed using image analysis (Image Pro-plus,
MediaCybernectics, Wokingham, UK) by dividing the intimal area by
the length of the vein segment, as described previously [22]. BrdU im-
munohistochemistry was performed as described previously [25].
VSMC migration was estimated by counting the number of cells in the
intima that are not labelled with BrdU and dividing by the length of
the vein segment. This method deﬁnes cells present within the intima
that have arisen by migration alone, and not by migration and prolifer-
ation, as previously described [26]. ISEL was performed as described
previously [27]. Immunohistochemistry for QBend10 was performed
as described previously [22]. Dual QBend10 and ISEL immunohisto-
chemistry was performed to quantify apoptosis in endothelial cells.
ISEL was performed as previously [27] and then after using the avidin
and biotin blocking kit (Vector) QBend10 staining was performed as
previously [22] but using Extravidin alkaline phosphatase and Fast
Red chromogen (Sigma).
2.14. Statistical analysis
Values are expressed asmean±SEM. Datawere analysed byANOVA
for multiple comparisons and the Student Newman Keuls post-test was
used. For experiments with two groups, the paired t-test was utilised
and the one-sample test was used for the endothelial cell coverage
analysis. Differences were considered signiﬁcant when p b 0.05.
The funding body was not involved in the interpretation of the data.
3. Results
3.1. Soluble N-cadherin reduced VSMC proliferation and migration
We observed that addition of 20–200 pM SNC-Fc signiﬁcantly
reduced VSMC proliferation in vitro (Fig. 1a), assessed by BrdU
incorporation. This was conﬁrmed with the 200 pM dose by immu-
nocytochemistry for proliferating cell nuclear antigen (PCNA), a
marker of proliferation (Fig. 1b). Addition of the same concentra-
tions of SNC-Fc also signiﬁcantly reduced VSMCmigration, assessed
by the wounding assay (Supplementary Fig. 1a), and this ﬁnding
was conﬁrmed with the 200 pM dose using the Transwell migration
assay (Supplementary Fig. 1c). Although migration was signiﬁcant-
ly reduced, the degree of the effect of SNC-Fc on VSMC migration
was small and was not dose-dependent (Supplementary Fig. 1a),
Fig. 1.N-cadherin reduced VSMC proliferation. a: Proliferation (percentage of BrdU positive human VSMCs) following 24 h treatmentwith 20, 100 or 200 pMFc or SNC-Fc in the presence
of bFGF and PDGF. * indicates a signiﬁcant difference from the Fc control, and $ indicates a signiﬁcant difference from SNC-Fc at other doses, p b 0.05, n = 3. Representative images of
immunocytochemistry for BrdU on VSMCs treated for 24 h with 200 pM Fc or SNC-Fc. Arrowheads indicate some positive nuclei (brown), negative nuclei are blue (haematoxylin).
Scale bars represent 25 μm. b: Proliferation (percentage of PCNA positive humanVSMCs) following 24 h treatmentwith 200 pMFc or SNC-Fc in the presence of bFGF and PDGF. * indicates
a signiﬁcant difference from the Fc control, p b 0.05, n = 3. Arrowheads indicate some positive nuclei (green), negative nuclei are blue (DAPI). Scale bars represent 20 μm.
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1b). Therefore, we focused all further experiments on the effects
of SNC-Fc on proliferation.
3.2. Soluble N-cadherin did not affect N-cadherin levels or β-catenin
signalling
We have previously demonstrated that N-cadherin levels are re-
duced and β-catenin signalling is increased in proliferating VSMCs [5].
Consequently, we examined whether N-cadherin levels and β-catenin
signalling were affected by treatment with SNC-Fc compared to Fc to
determine whether this contributed to the inhibition of proliferation.
Interestingly, SNC-Fc had no signiﬁcant effect on the levels of full length
N-cadherin in human VSMCs after stimulation of proliferation with
PDGF-BB and bFGF (Fig. 2a). Additionally, SNC-Fc treatment had no ef-
fect on the mRNA levels of the β-catenin target genes, cyclin D1 and
p21 (Fig. 2b) in human VSMCs.
To investigate the effect of SNC-Fc on TCF-dependent β-catenin sig-
nalling directly, we used VSMCs isolated from the aortas of TOPgal
transgenic mice. These mice have the β-galactosidase gene under the
control of TCF responsive elements so β-catenin/TCF signalling can be
assessed by quantiﬁcation of β-galactosidase [7,21]. We detected a sig-
niﬁcant increase in β-catenin signalling in proliferating cells compared
to quiescent cells, as assessed by immunocytochemistry for β-
galactosidase (45.4 ± 6.3 vs. 18.0 ± 5.1, % cells positive for β-
galactosidase) and by the galactolight luminescent assay for β-
galactosidase activity. However, SNC-Fc treatment during PDGF-BB
and bFGF induced proliferation had no effect on β-catenin signalling,
detected by the galactolight luminescent assay for β-galactosidase ac-
tivity and by immunocytochemistry for β-galactosidase (Fig. 2c and d,respectively).These data show that under these experimental condi-
tions, the mechanism by which SNC-Fc reduces proliferation is not
through inhibition of TCF dependent β-catenin signalling or by altering
full length N-cadherin protein levels.
3.3. FGFRwas essential for the anti-proliferative effect of soluble N-cadherin
Due to the lack of effect of SNC-Fc on β-catenin signalling and N-
cadherin levels we investigated an alternative mechanism. We focused
on FGFR signalling as we have previously shown that SNC-Fc can acti-
vate FGFR and reduce apoptosis [12].
Inhibition of FGFR using a synthetic inhibitor (SU5402) ablated the
anti-proliferative effect of SNC-Fc (Fig. 3a). This was conﬁrmed using
two different siRNA sequences for FGFR1 (the predominant FGFR in
human VSMCs, Fig. 3b). FGFR1 mRNA and protein levels were signiﬁ-
cantly reduced following siRNA treatment (Supplementary Fig. 1).
This suggested that FGFR was required for the anti-proliferative effect
of SNC-Fc. Unsurprisingly, FGFR1 siRNA itself signiﬁcantly reduced
VSMC proliferation.
Further support for this was gained by using mutated versions of
SNC-Fc, which prevent interactions with either N-cadherin or FGFR
[17]. Proliferation, as assessed by BrdU incorporation, was still reduced
by SNC-Fc when the N-cadherin binding site was mutated (SNC-Fc N-
Cadmut), suggesting that N-cadherin binding is not necessary for the
anti-proliferative effect of SNC-Fc (Fig. 3c). However, when the FGFR
binding site was mutated (SNC-Fc FGFRmut), proliferation could no
longer be reduced (Fig. 3c). To prove that the mutation prevents
the interaction of SNC-Fc with the FGFR, we have performed an im-
munoprecipitation. FGFR1-GFP was overexpressed, and cells were
treated with Fc/SNC-Fc or SNC-Fc FGFRmut. Immunoprecipitation
Fig. 2. SNC-Fc had no effect onβ-catenin signalling. a: RepresentativeWestern blots of N-cadherin andGAPDH proteins following 24 h treatmentwith 200 pMFc or SNC-Fc in the presence
of bFGF and PDGF. Chart shows densitometry analysis of N-cadherin normalised by GAPDH, n= 3. b: qPCR analysis of β-catenin target genes, cyclin D1 and p21 levels following 6 h treat-
ment with 200 pM Fc or SNC-Fc in the presence of bFGF and PDGF, normalised to 18S, n= 3. c: Galactolight assay (to measure β-galactosidase activity, and thereby β-catenin signalling)
measured in arbitrary units in TOPgal VSMCs treated with 200 pM Fc or SNC-Fc in the presence of bFGF and PDGF, n = 3. d: Representative images of dual immunocytochemistry for β-
galactosidase (green) and BrdU (red) on TOPgal VSMCs treated with 200 pM Fc or SNC-Fc in the presence of bFGF and PDGF. Chart shows the percentage of proliferating cells (BrdU
positive) that were positive for β-galactosidase, n = 3. Arrowheads indicate some positive cells (red nuclei and green cytoplasm). Scale bars represent 25 μm.
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Fc tag was performed, to show that only SNC-Fc, but not Fc nor
SNC-Fc FGFRmut were bound to the FGFR1-GFP (Fig. 3d (i)). To
prove that SNC-Fc FGFR1 remains otherwise functional, we have
shown that it can still bind to the full length N-cadherin molecule
(Fig. 3d (ii)). Full length N-cadherin was overexpressed using RAd
FLNC, as previously described [28]. Cells were then incubated with
200 pM Fc/SNC-Fc or SNC-Fc FGFRmut for 1 h, then lysed and West-
ern blotting performed for the Fc tag. As shown in Fig. 3d (ii), whilst
Fc has not bound to the cells, and therefore is not present in the cell
lysate, both SNC-Fc and SNC-Fc FGFRmut have bound, suggesting
that functionality has been retained.
To investigate the mechanism by which SNC-Fc reduced prolifera-
tion by binding to the FGFR, we looked at the effect of SNC-Fc on the nu-
clear localisation of FGFR. AMAXA nucleofection was utilised to
transfect human saphenous vein VSMCs with GFP labelled FGFR1
(transfection efﬁciency was 36.7 ± 3.3%), prior to treatment with
PDGF and bFGF and 20, 100 and 200 pM Fc or SNC-Fc. As observed by
Bryant et al. [16], we found that addition of bFGF and PDGF caused
nuclear translocation of the FGFR1 (Fig. 3e). Nuclear translocation
was prevented by addition of SNC-Fc, and this occurred in a dose
responsive manner (Fig. 3e). FGFR1 (SP/NLS) causes FGFR1 to
be constitutively nuclear. We utilised this plasmid to show that
when FGFR1 is constitutively nuclear, SNC-Fc cannot reduce VSMCproliferation (Fig. 3f), providing causal evidence that FGFR1 nuclear
translocation is the mechanism by which SNC-Fc reduces VSMC
proliferation.
3.4. Soluble N-cadherin reduced intimal thickening
As a result of the beneﬁcial effects on VSMC proliferation we aimed
to determine whether SNC-Fc could suppress intimal thickening. The
effect of SNC-Fc on intimal thickening was investigated using a well-
validated human ex vivo organ culture model [29–32]. Segments of
human saphenous vein were incubated in culture media containing
20 pM Fc or SNC-Fc for a period of 14 days. During this time an intima
forms on the lumenal surface of the vein due to proliferation andmigra-
tion of VSMCs [20]. SNC-Fc signiﬁcantly reduced intimal area (Fig. 4a–b,
Table 2) predominantly through inhibition of intimal cell proliferation,
as measured by the percentage of cells positive for BrdU incorporation
(Fig. 4c–d, Table 2). SNC-Fc also signiﬁcantly reduced the percentage
of cells positive for ISEL, amarker of apoptosis (Fig. 4 e–f, Table 2). How-
ever, there was no effect onmedial density or migration of cells into the
intima (indirectlymeasured as the number of non-BrdU labelled cells in
the intima, Table 2). Importantly, SNC-Fc signiﬁcantly increased endo-
thelial coverage. Endothelial coverage was measured as the length of
vein positive for QBend10 divided by the total length and expressed as
a percent of the Fc control (Fig. 4g–h). Endothelial coverage between
Fig. 3. FGF-Rwas essential for the anti-proliferative effect of soluble N-cadherin. a: Proliferation (percentage of BrdU positive human VSMCs) following treatment with SU5402 (an inhib-
itor of FGFR1) and 100 pM Fc or SNC-Fc, in the presence of bFGF and PDGF for 24 h. * indicates a signiﬁcant difference from the Fc control, n= 3. b: Proliferation (percentage of BrdU pos-
itive humanVSMCs) following siRNA for FGFR1 and treatment with 100 pMFc or SNC-Fc in the presence of bFGF and PDGF for 24 h. * indicates a signiﬁcant difference from the relevant Fc
control, n = 3. c: Proliferation (percentage of BrdU positive human VSMCs) following 24 h incubation with bFGF and PDGF and 100 pM Fc, SNC-Fc or SNC-Fc with either the N-cadherin
binding site mutation (SNC-Fc N-cadmut) or FGF-R binding site mutated (SNC-Fc FGFRmut). * indicates a signiﬁcant difference from the Fc control, n = 3. d: Western blot for Fc-tag in
VSMCs overexpressing FGFR1GFP and incubated with Fc/SNC-Fc/SNC-Fc for 1 h, before immunoprecipitation for GFP tagged FGFR and Western blotting (i). Western blot for Fc-tag in
VSMCs overexpressing full length N-cadherin and incubated with Fc/SNC-Fc/SNC-Fc FGFR for 1 h, before lysis and Western blotting (ii). e: The percentage of cells with nuclear FGFR fol-
lowingAMAXA transfectionwith FGFR1 plasmid and treatmentwith either serum freemedia (SF), bFGF andPDGF (GF), and 20, 100or 200 pMFc or SNC-Fc plusGF. * indicates a signiﬁcant
difference from SF control, # indicates a signiﬁcant difference fromGF and Fc plus GF, n= 3. Representative images to show nuclear translocation of FGFR1 for the 200 pMdose. Scale bars
represent 10mm. Yellow arrowheads indicate cells with nuclear FGFR1 (green), white arrowheads indicate cells with cytoplasmic FGFR1. Nuclei have been psuedocoloured in red. f: Pro-
liferation (percentage of BrdU positive human VSMCs) following transfection with FGFR1(SP/NLS), a constitutively nuclear form of FGFR1, and treatment with 200 pM Fc or SNC-Fc in the
presence of bFGF and PDGF for 24 h. * indicates a signiﬁcant difference from SF, n = 3.
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segment to segment reproducibility was high (coefﬁcient of variation
=0.06 ± 0.01). Dual immunohistochemistry for apoptosis (ISEL) and
endothelial cells (Q-Bend10) showed that SNC-Fc treatment signiﬁcant-
ly reduced endothelial cell apoptosis (Fig. 4i–l, Table 2), which agrees
with our previous in vitro data [12].3.5. Soluble N-cadherin had no effect on endothelial cell proliferation and
migration
Endothelial cell coverage is reliant on endothelial cell survival,
migration and proliferation. We have previously published that SNC-
Fc increases endothelial cell survival [12], which therefore contributes
Fig. 4. SNC-Fc reduced intimal thickening in an ex vivo organ culturemodel. Representative
images of: a and b: Elastin van Gieson staining to show intimal size. c and d: Immunohisto-
chemistry for BrdU incorporation (brown nuclei: proliferation). e and f: ISEL (brown nuclei:
apoptosis). g and h: Immunohistochemistry for QBend10 (brown colour: endothelial cells).
i and j: Dual immunohistochemistry for QBend10 (pink, endothelial cells) and ISEL (brown
nuclei, apoptosis). k and l: Higher power images of the dual QBend10 (pink) and ISEL
(brown) to clearly show the double staining in i. Dotted line delineates the intimal:medial
boundary. Arrowheads indicate some of the positive cells. Scale bars in a-d and g and h
represent 20 μm, scale bars in e, f, i, j, k and l represent 40 μm, n = 5.
Table 2
Effect of SNC-Fc on human saphenous vein organ culture model.
Fc SNC-Fc
Intimal area/length of vein segment (μm) 8.68 ± 1.85 1.28 ± 0.60⁎
% intimal cells BrdU positive 30.4 ± 7.2 13.6 ± 3.6⁎
% medial cells BrdU positive 11.6 ± 3.1 5.0 ± 1.3⁎
Medial density (cell/m2 × 1000) 14.13 ± 3.3 15.44 ± 2.8
Migration into intima (non-BrdU cells/length ×
1000)
2.9 ± 2.0 2.5 ± 0.8
% intimal cells ISEL positive 6.23 ± 1.6 3.06 ± 0.73⁎
% medial cells ISEL positive 3.18 ± 0.60 1.95 ± 0.22⁎
Endothelial coverage (fold change from Fc) 1 ± 0 2.92 ± 0.68⁎
% endothelial cells ISEL positive 9.44 ± 1.58 3.49 ± 1.0⁎
Mean ± SEM.
⁎ Indicates a signiﬁcant difference from the Fc control sample, paired Student's t-test, p
b 0.05, n = 5.
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SNC-Fc on endothelial cell (HUVEC) proliferation and migration. How-
ever, 20–200 pM of SNC-Fc did not reduce endothelial cell proliferation
(as assessed by BrdU incorporation) or migration (as assessed by the
scratch wound assay) compared to Fc control (Fig. 5 a and b).4. Discussion
VSMC proliferation and migration are major contributors to intimal
thickening and restenosis after clinical interventions for atherosclerosis
such as stenting and vein grafting, and cause high failure rates of
these interventions [2,33]. Consequently, anti-proliferative and
anti-migratory strategies are highly sought after for improving vein
graft patency and for use in drug-eluting stents. The major problem
with the currently available anti-proliferative treatments is that
they have a detrimental effect on re-endothelialisation. Therefore, a
drug which reduces VSMC proliferation and/or migration, but has
no effect, or increases endothelial cell proliferation, migration and/
or survival is desirable. In this study, we found that SNC-Fc signiﬁ-
cantly reduced VSMC proliferation, and to a lesser extent migration,
whilst having no effect on HUVEC proliferation and migration
in vitro. Using a human saphenous vein ex vivo organ culture
model of intimal thickening, we showed that SNC-Fc signiﬁcantly
reduced intimal area, whilst reducing endothelial cell apoptosis
and thereby increasing endothelial coverage. This study suggests
that SNC-Fc may have potential as a therapeutic for restenosis.
We have previously demonstrated that full length N-cadherin
inhibits VSMC proliferation [7], and that cadherin:catenin complexes
are dismantled during proliferation in cultures of isolatedhuman saphe-
nous vein VSMCs [5]. In this study we have also shown that SNC-Fc, a
potentially useful therapeutic soluble molecule, signiﬁcantly inhibited
VSMC proliferation. This corroborates a previous observation that a
soluble VE-cadherin retarded endothelial cell proliferation [34]. In con-
trast, our study revealed that SNC-Fc had no signiﬁcant effect on HUVEC
migration or proliferation. Previous studies in endothelial cells have
shown that SNC-Fc increased endothelial cell migration using the
wounding assay and angiogenesis in the cornea [11]. The discrepancy
may be the result of cell type and species differences, or since we
utilised considerably lower doses (2–200 pM) of SNC-Fc compared to
the previous study (56–112 nM). A recent study in isolated cells has
suggested that atorvastatin (but not other statins) more potently
reduced VSMC proliferation than EC [35], but our study identiﬁes SNC
as an agent that has no effect on EC proliferation whilst potently re-
ducing VSMC proliferation. Moreover, we illustrate using our organ
culture model enhance EC coverage of vein segments as a result of
SNC treatment.
N-cadherin mediates directed cell migration by increasing cell-cell
adhesion in various cell types (for example [36,37]). We have also
shown that full length N-cadherin also signiﬁcantly increased cell-cell
contacts in VSMCs [7]. SNC-Fc has the opposite effect, and signiﬁcantly
reduces both the ability of single VSMCs to aggregate and form cell–
cell adhesions [12], indicating that SNC-Fc acts as a mimetic interfering
with cell-cell association. As cell–cell contacts are important for directed
migration, this provides a potential mechanism for how SNC-Fc signiﬁ-
cantly reduced VSMC migration. However, as seen in Supplementary
Fig. 5. SNC-Fc had no effectHUVEC proliferation andmigration. a: Proliferation (percentage of BrdUpositiveHUVECs) following 24h incubationwith 20, 100 or 200pMFc or SNC-Fc, in the
presence of 2% FCS, n = 3. Arrowheads indicate BrdU positive cells (brown), negative cells have blue nuclei (haematoxylin). Scale bars represent 20 μm. b: Distance migrated in μm after
18 h (scratch wound assay) by HUVECs treated with 20, 100 or 200 pM Fc or SNC-Fc, in the presence of 2% FCS, n = 3. Scale bars represent 100 μm. Arrows indicate the wound edges.
60 C.A. Lyon et al. / Vascular Pharmacology 78 (2016) 53–62Fig. 1, the effect on migration is limited, and not as large as for
proliferation.
We have used both bFGF and PDGF to induce proliferation in the
in vitro experiments. Due to the fact that PDGF results in cellular release
of endogenous bFGF [38], using these growth factors individually was
not useful in teasing out any speciﬁc effects of bFGF compared to PDGF.
When we investigated the mechanism by which SNC-Fc reduced
VSMC proliferation, we anticipated that SNC-Fc would act as a mimetic,
binding full lengthN-cadherin at the cellmembrane andmaking the cell
believe it is participating in a cell–cell junction, and therefore retarding
proliferation.We predicted that this would result in accumulation of N-
cadherin andβ-catenin at the cell membrane. However, under these ex-
perimental conditions, we saw no change in the levels of N-cadherin in
the cell, and no change in TCF dependentβ-catenin signalling, nor in the
levels of β-catenin target genes (cyclin D1 and p21). We have previ-
ously shown that N-cadherin is higher in quiescent VSMC than in
proliferating VSMCs [5], suggesting that it is lost during prolifera-
tion. However, we did not observe this change in N-cadherin levels
in these experiments, suggesting that SNC-Fc does not interferewith N-cadherin levels. This was unexpected, as N-cadherin and
β-catenin play pivotal roles in VSMC proliferation.
Consequently, we examined an alternativemechanism involving the
FGFR. N-cadherin shares anHAVbindingmotif and can interactwith the
FGFR [13,14,39,40], and we have previously shown that SNC-Fc can ac-
tivate FGFR signalling [12]. Therefore, we investigated whether FGFR1,
the predominant FGF receptor expressed by human saphenous
VSMCs, was involved in the anti-proliferative effect of SNC-Fc. Firstly,
we used a chemical inhibitor of FGFR, SU5402, which prevented the
anti-proliferative effect of SNC-Fc. At this dose, SU5402, is shown to be
speciﬁc for the FGFR and have no inhibitory effect on the PDGF receptor.
We conﬁrmed this using two separate siRNA sequences, which showed
the same result: thatwhen FGFR is knocked down, SNC-Fc can no longer
reduce proliferation. Unfortunately, but understandably, siRNA knock-
down of FGFR1 caused a reduction of proliferation. This complicates
the results, as it is possible that SNC-Fc is just not able to reduce prolif-
eration any further than it has been already. However, we have seen
levels of proliferation lower than ~5% when we quiesce the cells with
serum free medium, suggesting that it is possible. We believe that
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FGFR1 is involved in this mechanism.
To provide additional evidence for the interaction of SNC-Fc and
FGFR1, we created mutations which prevented binding to either the
FGFR or N-cadherin. We found that when the N-cadherin binding site
wasmutated, this form of SNC-Fc (SNC-Fc N-cadmut) could still reduce
proliferation. However, when the FGFR binding site was mutated, this
form of SNC-Fc (SNC-Fc FGFRmut) could no longer reduce VSMC prolif-
eration, suggesting that this interaction is vital for the anti-proliferative
effect of SNC-Fc. Additionally, we have showndirect evidence, bymeans
of an immunoprecipitation, that SNC-Fc and the FGFR can interact, and
that this interaction is ablated by the mutation of the FGFR binding
site. We can also show that SNC-Fc FGFRmut can still bind to N-
cadherin on the cell surface, indicating that the mutation has not
disrupted other functions of SNC-Fc, nor its tertiary protein structure.
It appeared counterintuitive to us that SNC-Fc could be binding to
the FGF-R and reducing proliferation. Especially so, as we have previ-
ously published that when bound to the FGF-R, SNC-Fc can activate PI-
3 kinase and Akt signalling, resulting in increased cell survival [12].
This is a prime example of howdifferent cellular situations and the pres-
ence of different factors in the cellular milieu can affect the signalling
outcome.
It is known that when FGF binds to the FGFR, they are co-
internalised and the complex translocates to the nucleus, where FGFR
acts as a general transcription regulator, activating the transcription of
genes, such as FGF-2 and CREB, which are essential for proliferation
[15]. We postulated that binding of SNC-Fc to FGFR1 (in the presence
of bFGF) may prevent the internalisation and nuclear translocation of
FGFR, and thus reduce proliferation. Using a GFP labelled FGFR1, we
conﬁrmed that in the presence of bFGF, FGFR1 is translocated to the
nucleus [15,16]. Furthermore, we showed that this translocation was
prevented by the addition of SNC-Fc. The percentage of cells with nucle-
ar FGFR1 was SNC-Fc dose dependent, as was the inhibition of prolifer-
ation, suggesting that these events are linked. We also showed that
when FGFR1 is constitutively nuclear, SNC-Fc cannot reduce VSMC pro-
liferation, providing further evidence that SNC-Fc reduces proliferation
by preventing nuclear translocation of FGFR1.
The identiﬁcation of the FGFR binding site alone as the active site is
extremely advantageous as it indicates the possibility of designing
novel speciﬁc peptides which can be evaluated as a smaller therapeutic
in the future.
The ex vivo human saphenous vein organ culture model of intimal
thickening is an extremely useful, robust and relevant model of intimal
thickening [20,27]. Importantlywe showed that SNC-Fc reduced intimal
thickening by approximately 85% in this model. This appeared to be the
result of retarded proliferation in themedia and intima. Therewas how-
ever, no effect onmedial density, which is reassuring as reducingmedial
density could result in thinning and weakening of the graft. SNC-Fc also
reduced apoptosis in the media and the intima, which at ﬁrst may ap-
pear counter-intuitive, as one would predict that reducing apoptosis
would increase intimal cell number. However, the rates of apoptosis in
this model are relatively low and therefore may have only a small im-
pact on total cell number. In addition, when we performed dual immu-
nohistochemistry for endothelial cells and ISEL, it was clear thatmany of
the apoptotic intimal cells were endothelial cells. SNC-Fc inhibited en-
dothelial cell apoptosis in the organ culture model in a similar manner
as we previously observed in vitro [12], which presumably contributes
to the increased endothelial coverage. Additionally, the anti-apoptotic
effect of SNC-Fc on endothelial cells could indirectly reduce VSMC pro-
liferation. Vascular endothelial cells constitutively express endothelial
nitric oxide synthase, resulting in production of nitric oxide, which
inhibits proliferation of VSMCs [41]. Consequently, the enhanced endo-
thelial coverage will result in higher levels of nitric oxide and result in
down-regulation of VSMC proliferation.
In summary, this study highlights SNC-Fc as a potential therapeutic
agent for late vein graft failure and also in-stent restenosis, as it retardsintimal thickening via beneﬁcial actions on VSMCs and endothelial cells.
We showed for the ﬁrst time that SNC-Fc signiﬁcantly reduced intimal
cell proliferation, whilst having no detrimental effect on endothelial
cell proliferation and migration. Importantly, we demonstrate SNC-Fc
signiﬁcantly reduced intimal area, and increased endothelial coverage
in the organ culture model of intimal thickening. Moreover, the identi-
ﬁcation of the active site of SNC-Fc could lead to production of a smaller
clinically useful peptide, which may be used as a stent coating or deliv-
ered directly to the vein graft.
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